MYRIAD GENETICS INC

# Myriad Genetics Inc (MYGN)

Myriad Genetics is a molecular diagnostics company that develops and commercializes DNA-based tests for oncology, women's health, and pharmacogenomics. The company's test portfolio includes hereditary cancer screening (MyRisk), companion diagnostics for cancer treatment selection (BRACAnalysis CDx, MyChoice CDx), and tumor prognostic assessments (Prolaris for prostate cancer, EndoPredict for breast cancer). The company also offers prenatal and carrier screening tests, including non-invasive prenatal screening and gender prediction tests, alongside psychiatric pharmacogenomics testing (GeneSight) to guide mental health medication selection.

The company operates through partnerships with major medical institutions and diagnostic companies, including license collaborations with Illumina, Mayo Clinic, MD Anderson Cancer Center, and the Institut Curie. Myriad's revenue streams derive from laboratory testing services provided directly to healthcare providers and patients. The company maintains approximately 2,700 full-time employees and operates from its headquarters in Salt Lake City, Utah. As a public company traded on Nasdaq, Myriad operates primarily in the United States, serving oncologists, obstetricians, primary care physicians, and mental health practitioners through its laboratory testing platform.